Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Down 5.6% in August

Dyadic International, Inc. (NASDAQ:DYAI) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 142,400 shares, a decrease of 5.6% from the August 15th total of 150,900 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average daily volume of 50,400 shares, the short-interest ratio is presently 2.8 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a report on Monday, July 8th.

Dyadic International Trading Down 7.2 %

Shares of DYAI stock opened at $1.16 on Thursday. The stock has a market capitalization of $33.91 million, a P/E ratio of -4.14 and a beta of 0.74. Dyadic International has a fifty-two week low of $1.13 and a fifty-two week high of $2.67. The company has a debt-to-equity ratio of 1.72, a quick ratio of 5.39 and a current ratio of 5.39. The company has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.56.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The company had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $1.00 million. Dyadic International had a negative return on equity of 145.95% and a negative net margin of 428.86%. During the same period in the prior year, the company posted ($0.07) EPS. Equities research analysts predict that Dyadic International will post -0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. grew its stake in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 847,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the period. Chapin Davis Inc. owned 2.90% of Dyadic International worth $1,254,000 at the end of the most recent reporting period. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.